Financial Performance - Net loss attributable to common stockholders for Q4 2024 was $8.2 million, or $6.29 per share, compared to a net loss of $1.1 million, or $1.43 per share, in Q4 2023[10]. - For the full year 2024, net loss attributable to common stockholders was $12.9 million, or $12.52 per share, compared to a net loss of $5.3 million, or $7.05 per share, in 2023[14]. Expenses - Research and development expenses for Q4 2024 were $2.3 million, a 567% increase from $0.3 million in Q4 2023[8]. - General and administrative expenses for Q4 2024 were $5.2 million, up 575% from $0.8 million in Q4 2023, primarily due to nonrecurring transaction costs[9]. Capital and Funding - The company converted $19.5 million in debt to equity, significantly improving its balance sheet[5]. - A recent capital raise of $4.8 million, combined with existing cash, provides operational runway through Q1 2026[5]. - As of December 31, 2024, Dogwood Therapeutics had cash totaling $14.8 million, sufficient to fund operations through Q1 2026[14]. Assets and Liabilities - Total assets increased to $94.3 million as of December 31, 2024, compared to $4.2 million in 2023[23]. - Total liabilities rose to $30.0 million as of December 31, 2024, compared to $0.4 million in 2023[23]. Clinical Development - Dogwood Therapeutics commenced dosing in its Halneuron® Phase 2b CINP program, with interim data expected in Q4 2025[5].
Virios Therapeutics(VIRI) - 2024 Q4 - Annual Results